NGNE (Neurogene) Other Long-Term Liabilities : $0.05 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Neurogene Other Long-Term Liabilities?

Neurogene's other long-term liabilities for the quarter that ended in Dec. 2024 was $0.05 Mil.

Neurogene's quarterly other long-term liabilities declined from Jun. 2024 ($0.05 Mil) to Sep. 2024 ($0.05 Mil) but then increased from Sep. 2024 ($0.05 Mil) to Dec. 2024 ($0.05 Mil).

Neurogene's annual other long-term liabilities declined from Dec. 2022 ($244.37 Mil) to Dec. 2023 ($0.20 Mil) and declined from Dec. 2023 ($0.20 Mil) to Dec. 2024 ($0.05 Mil).

Neurogene Other Long-Term Liabilities Historical Data

The historical data trend for Neurogene's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Neurogene Other Long-Term Liabilities Chart

Neurogene Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Other Long-Term Liabilities

177.91

244.37

0.20

0.05

Neurogene Quarterly Data
	Dec21	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Other Long-Term Liabilities	Get a 7-Day Free Trial						0.20	0.20	0.05	0.05	0.05

Neurogene Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Neurogene Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Neurogene's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Neurogene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Neurogene Inc (NAS:NGNE) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

UU8:Germany

Address

535 W 24th Street, 5th Floor, New York, NY, USA, 10011

Website

https://www.neurogene.com

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.